Big names including AbbVie, Novartis, Amgen, Sanofi, Merck, Eli Lilly, Pfizer, Johnson & Johnson and Biogen all have been involved in recent lawsuits regarding biosimilar medicines, according to a Reuters article.

Manufacturers are not only protecting their high-priced drugs from biosimilars, but also challenging competitors' patent claims.

The article states that Novartis CEO Joe Jimenez is predicting biosimilar discounts will be up to 75 percent, so makers of these drugs are fighting hard to protect their high-profit products for as long as possible.

Read the full story